Families who have already tried other options may ask about TB006, an investigational drug for Alzheimer’s disease. Universal Neurological Care offers TB006 to eligible patients through the Expanded Access Program (EAP), which the FDA allows when there is no satisfactory alternative available.
TB006 is an investigational drug developed by TrueBinding. In clinical trials, TB006 is currently being evaluated for its potential effects on memory and cognition. TrueBinding’s Phase 2b trial is expected to begin in early 2027. TB006 is experimental and still undergoing clinical testing, and it is not yet FDA approved. Its safety and effectiveness have not been established.
Interested patients or caregivers can contact us to schedule a screening consultation. Our team will:
"Universal Neurocare is a very high-performing and well-organized operation… I drive quite a distance to get there but it is worth it. I am heard, helped there and known by name." - E.L., a Universal Neurological Care patient
To learn more, visit our TB006 page or call Universal Neurological Care at (904) 404-7044 to schedule a consultation with Dr. Asad.




